You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 156 No. 6, June 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Pediatrics, Other
 •Alert me on articles by topic

Comparison of 2 Iron Doses in Infants Receiving Recombinant Human Erythropoietin Therapy

Shahid Nazir, MD; Ricardo L. Peverini, MD; Douglas D. Deming, MD; Andrew O. Hopper, MD; Nidia R. Vyhmeister, MD

Arch Pediatr Adolesc Med. 2002;156:540-544.

Objective  To compare iron sufficiency in premature infants receiving high-dose recombinant human erythropoietin (r-HuEPO), 1200 IU/kg per week, supplemented with 6 or 12 mg/kg per day of enteral iron.

Design  We conducted a prospective, double-blind, controlled study of premature infants receiving r-HuEPO therapy, randomly assigned to receive 2 different doses of iron. Measurements of ferritin, iron, total iron-binding capacity, reticulocyte count, hemoglobin level, and hematocrit were obtained at baseline, 4, and 6 weeks. Transferrin saturation was calculated; the number of blood transfusions and the incidences of sepsis were recorded.

Setting  This study was performed in the neonatal intensive care unit at Loma Linda University Children's Hospital, Loma Linda, Calif.

Subjects  Infants with a gestational age of 32 weeks or younger, older than 7 days, and receiving r-HuEPO therapy from March 1, 1997, to June 30, 1998, were eligible for the study. Infants were randomly assigned to receive 6 mg/kg per day or 12 mg/kg per day of enteral iron during a course of r-HuEPO therapy for 4 to 6 weeks.

Results  Sixty-four infants were enrolled in the study. Twelve infants did not complete the study; 52 completed 4 weeks and 41 completed 6 weeks of the study. While ferritin levels and transferrin saturation decreased in both groups over the study period, there were no differences between the 2 study groups.

Conclusions  Infants receiving high-dose r-HuEPO therapy (1200 IU/kg per week) decrease their ferritin levels (measure of iron stores) even when receiving high enteral iron supplementation. Given that the ferritin levels were similar between the 2 groups, we speculate that the additional iron either was not absorbed or was not stored.


From the Department of Pediatrics, Loma Linda University School of Medicine (Drs Peverini, Deming, Hopper, and Vyhmeister), Loma Linda, Calif. Dr Nazir is in private practice in Colton, Calif.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Is supplementary iron useful when preterm infants are treated with erythropoietin?
Ridley et al.
Arch. Dis. Child. 2006;91:1036-1038.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.